Animal studies are crucial to the development of therapeutic drugs for atherosclerosis and NAFLD. A gene-targeted mouse model of atherosclerosis has been created at the Jackson Laboratory in Bar Harbor, Maine, USA, in which C57BL/6J mice homozygous for the Apo Etm1Unc mutation demonstrate a functional knockout of the antiatherogenic apolipoprotein E (ApoE) gene involved in cholesterol metabolism [7, 8] . This ApoE-knockout (ApoE-KO) mouse has been widely used in atherosclerosis research because of its propensity to spontaneously develop hypercholesterolemia and atherosclerotic lesions similar to those found in humans [9, 10] . In addition to atherosclerotic lesions, ApoE-KO mice over 6-months of age develop hepatic steatosis and fibrosis [11] .
Atherosclerotic lesions in ApoE-KO mice are histopathologically classified into 3 categories by stages [12] In a practical sense, mice are the preferred research animal in terms of economical space and husbandry requirements, and the ability to generate specific gene equivalency between mouse and man is extremely useful in translational research. Because both atherosclerosis and NAFLD normally occur in this line and are promoted by dietary fat, ApoE-KO mice provide a functional model to aid in the elucidation of molecular mechanisms and the development of therapeutic agents for treatment of human atherosclerosis and NAFLD. 
